Open the link, keep the context
The sources behind the claims
These are the sources linked in Fit Peptide. The short notes say what each one helps answer, and where the answer stops.
- Study
- Who took part, and what changed?
- Label
- Which use and which cautions?
- FDA
- What does the status mean?
Pick the source for your question
A mouse study, a human trial and a drug label do different jobs. The notes below keep those jobs clear. A link lets you check a claim; it doesn't turn every finding into a treatment option.
Keep the answer attached to its setting
For a result about weight, look for who took part and how long they were followed. For a fat measurement, keep the location in view. And for a movement claim, check whether anyone actually tested movement in people.
MOTS-c
MOTS-c and metabolic homeostasis
Lee and colleagues · Cell Metabolism · 2015
The first MOTS-c paper used cells and mice. It explains the interest in metabolism, but cannot establish weight loss or safety in people given MOTS-c.
MOTS-c, exercise and physical performance
Reynolds and colleagues · Nature Communications · 2021
Mice given MOTS-c performed better in movement tests. The human part measured the body's own MOTS-c after exercise. It wasn't a human treatment test.
FDA's withdrawn nominations and safety concerns
U.S. Food and Drug Administration · page current as of April 22, 2026
FDA lists MOTS-c among substances nominated but withdrawn. Its safety concerns remain. The page date isn't an individual withdrawal date, and withdrawal isn't approval for compounding.
FDA staff's review of MOTS-c
U.S. Food and Drug Administration · July 2026 advisory meeting material
FDA staff describe missing human treatment and safety data and possible immune reactions. This review isn't a final agency decision or a record of an advisory vote.
Tesamorelin
EGRIFTA WR (tesamorelin) prescribing information
DailyMed · U.S. prescribing information
The approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The label says it isn't for weight loss and lists hormone, blood sugar and other cautions.
Tesamorelin, visceral fat and liver fat
Stanley and colleagues · JAMA · 2014
This six-month study involved adults with HIV and excess abdominal fat. Scans showed reduced visceral fat compared with placebo. That location and group belong with the result.
Tesamorelin during treatment and after withdrawal
Falutz and colleagues · AIDS · 2008
This 52-week study followed adults with HIV and excess abdominal fat. Visceral fat reaccumulated after switching to placebo at week 26; continued treatment maintained a reduction through week 52. It does not establish the same result in another population.
Tirzepatide
ZEPBOUND (tirzepatide) prescribing information
DailyMed · U.S. prescribing information
The Zepbound label gives the approved uses and warnings. Its boxed thyroid warning comes from rat findings; whether these tumors occur from tirzepatide in people is unknown.
MOUNJARO (tirzepatide) prescribing information
DailyMed · U.S. prescribing information
Mounjaro contains tirzepatide and has a type 2 diabetes use. Its label differs from Zepbound's. The shared ingredient doesn't make the approved uses interchangeable.
SURMOUNT-1: tirzepatide in adults without diabetes
Jastreboff and colleagues · New England Journal of Medicine · 2022
Adults without diabetes who had obesity, or overweight with a weight-related complication, lost more weight on tirzepatide than placebo over 72 weeks. Group averages aren't personal forecasts.
SURMOUNT-4: continuing or withdrawing tirzepatide
Aronne and colleagues · JAMA · 2024
In this adult weight-maintenance study, participants first received tirzepatide for 36 weeks. The 670 participants who completed that phase were assigned to continue or switch to placebo for 52 weeks. The switch group regained weight on average, rather than everyone regaining everything.
Products and approval
What FDA approval does not cover in compounding
U.S. Food and Drug Administration · compounding questions and answers
The FDA page explains why a compounded medicine isn't an FDA-approved product. A preparation doesn't inherit another product's approval just because the ingredient name matches. Product identity matters alongside the ingredient.